Home > Insider Trading > Filing (0000899243-21-040777)

Filing Details

Accession Number:: 0000899243-21-040777
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-10-20 16:38:25
Reporting Period:: 2021-10-18

Accepted Time:: 2021-10-20 16:38:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1720725	Oyster Point Pharma Inc.	OYST	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1456589	Versant Ventures Iv, Llc	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1456590	Versant Venture Capital Iv, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1456591	Versant Side Fund Iv, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1687880	Versant Venture Capital Vi, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1765253	Versant Vantage I, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777651	Versant Vantage I Gp, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777652	Versant Ventures Vi Gp-Gp, Llc	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777653	Versant Vantage I Gp-Gp, Llc	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777654	Versant Ventures Vi Gp, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-10-18	303,614	$14.63	1,057,976	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-10-18	1,912	$14.63	6,518	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-10-18	242,943	$15.09	815,033	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-10-18	1,531	$15.09	4,987	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,236,888	Direct
Common Stock	1,003,658	Indirect	See Footnotes

Footnotes

The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by each of Versant Venture Capital IV, L.P. ("Versant IV") and Versant Side Fund IV, L.P. ("Versant Side Fund IV").
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $14.00 to $14.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
Shares held by Versant IV. Versant Ventures IV, LLC ("Versant Ventures IV") is the sole general partner of Versant IV. William J. Link, a member of the Issuer's board of directors, is a managing member of Versant Ventures IV and may be deemed to share voting and dispositive power over the shares held by Versant IV. Each of Versant Ventures IV and William J. Link disclaims beneficial ownership of the shares held by Versant IV, except to the extent of their respective pecuniary interests therein. William J. Link is a director of the Issuer and, accordingly, files separate Section 16 reports.
Shares held by Versant Side Fund IV. Versant Ventures IV is the sole general partner of Versant Side Fund IV. William J. Link, a member of the Issuer's board of directors, is a managing member of Versant Ventures IV and may be deemed to share voting and dispositive power over the shares held by Versant Side Fund IV. Each of Versant Ventures IV and William J. Link disclaims beneficial ownership of the shares held by Versant Side Fund IV, except to the extent of their respective pecuniary interests therein. William J. Link is a director of the Issuer and, accordingly, files separate Section 16 reports.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $15.00 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the sole general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") and Versant Ventures VI GP is the sole general partner of Versant VI. Clare Ozawa, a member of the Issuer's board of directors, is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP and Clare Ozawa disclaims beneficial ownership of the shares held by Versant VI, except to the extent of their respective pecuniary interests therein. Clare Ozawa is a director of the Issuer and, accordingly files separate Section 16 reports.
Shares held by Versant Vantage I, L.P. ("Versant Vantage"). Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("Versant Vantage I GP") and Versant Vantage I GP is the sole general Partner of Versant Vantage. Clare Ozawa, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage. Each of Versant Vantage I GP-GP, Versant Vantage I GP, and Clare Ozawa disclaims beneficial ownership of the shares held by Versant Vantage, except to the extent of their respective pecuniary interests therein. Clare Ozawa is a director of the Issuer and, accordingly files separate Section 16 reports.